ArticlePloS one2024
Hydrothermal synthesis of Zingiber/ZnO for enhanced photodegradation of ofloxacin antibiotic and reactive red azo dye (RR141).
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The examination of photocatalyst powders for the total removal of pollutants from aqueous solutions is a vital research subject within the realm of environmental preservation. The objective of this study is to develop a photocatalyst heterojunction consisting of Zingiber/ZnO-H for the degradation of both the reactive red dye (RR 141) and ofloxacin antibiotic in wastewater. The current investigation outlines the process of synthesising a composite material by combining Zingiber montanum extract with zinc oxide (ZnO) by a hydrothermal method. The synthesis was conducted at a temperature of 180°C for a period of 4 hours. Consequently. The photocatalyst with a constructed heterojunction shown a notable enhancement in its photocatalytic activity as a result of the improved efficiency in charge separation at the interface. The application of economically viable solar energy facilitated the complete eradication of harmful pollutants through the process of detoxification. The removal of impurities occurs by a process that follows a first-order kinetics. Among the pollutants, RR141 demonstrates the greatest rate constant at 0.02 min-1, while ofloxacin has a rate constant of 0.01 min-1. The assessment of the stability of the produced photocatalyst was conducted after undergoing five cycles. This study additionally investigated the influence of sunshine on degradation, uncovering degradation rates of 97% for RR141 and 99% for ofloxacin when exposed to UV Lamp, and degradation rates of 97% for RR141 and 95% for ofloxacin when exposed to Solar Light.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.